A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)
The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with locally advanced or metastatic non-squamous NSCLC whose tumors express PD-L1.
This is a Phase III, two-arm, randomized, double-blind, global, multicenter study assessing the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a 1L treatment for patients with locally advanced or metastatic non-squamous NSCLC whose tumors express PD-L1 (TC ≥ 1%).
Inclusion Criteria:
Exclusion Criteria:
information.center@astrazeneca.com1-877-240-9479
CABA, 1425, Argentina
Gyöngyös - Mátraháza, 3200, Hungary
Amagasaki-shi, 660-8550, Japan
Kawagoe-shi, 350-8550, Japan
Kawasaki-shi, 216-8511, Japan
Kitaadachi-gun, 362-0806, Japan
Kitakyushu-shi, 807-8555, Japan
Matsusaka-shi, 515-8544, Japan
Ota-shi, 373-8550, Japan
Saitama-shi, 338-0001, Japan
Shinjuku-ku, 160-0023, Japan
Sunto-gun, 411-8777, Japan
Takaoka-shi, 933-8555, Japan
Songpa-gu, 05505, South Korea
Greater London, SW3 6JJ, United Kingdom